Table 1.
SEs’ roles in hematological malignancy.
| Disease† | Phenotype‡ | Upstream (O/S) and potential therapeutic targets§ | Regulation of SEs | Downstream | References |
|---|---|---|---|---|---|
| AL | DLT | BETi: OTX015 (S) | ↓ | NM | Berthon et al., 2016 |
| AML | P, A | NPM1; BETi: I-BET151 (S) | ↓ | NM | Dawson et al., 2014 |
| AML | D, P, G | CDK8, 19 (O) | ↓ | STAT1 S727 | Nitulescu et al., 2017 |
| AML | D | NCD38 (S), LSD1 (O) | ↓/↑ | GFI1, ERG | Sugino et al., 2017 |
| AML | A | BETi: BI894999 (S) | ↓ | p-Ser2 RNA polymerase II | Gerlach et al., 2018 |
| B-ALL | D | IKAROS (S) | ↓ | Sykb, CD79b | Hu Y. et al., 2017 |
| B-ALL | A, P, D, T | STAT5 (O); PAX5, EBF, IKAROS (S) | ↑/↓ | NM | Katerndahl et al., 2017 |
| BL and IL | A | EBV (O) | ↑ | CFLAR, IRF2 | Ma et al., 2017 |
| BPDCN | A | TCF4 (O), BETi: JQ1 (S) | ↓ | NM | Ceribelli et al., 2016 |
| CLL | A, TG | SNP rs539846 (O) | ↓ | BCL2-BMF | Kandaswamy et al., 2016 |
| CLL | P | PAX5 (O) | ↑ | BCL2, CXCR4, CD83… | Ott et al., 2018 |
| DLBCL and FL | D | CREBBP (S) | ↓ | BCL6, MEF2B, MEF2C… | Zhang et al., 2017 |
| ETP-ALL | D | NPi:GSIs (S) | ↓ | MYC | Knoechel et al., 2015 |
| LP | DLT | BETi: OTX015 (S) | ↓ | NM | Amorim et al., 2016 |
| LP and LK | P | CREBBP/EP300 (O); CBP30 (S) | ↑/↓ | GATA1, MYC | Garcia-Carpizo et al., 2018 |
| MM | P | JQ1 | ↓ | MYC | Loven et al., 2013 |
| MM | DLT | BETi: OTX015 (S) | ↓ | NM | Amorim et al., 2016 |
| PEL | P, A | IMiDs, JQ-1, IBET151, PFI-1 (S) | synergy | IRF4, IKZF1 (but not IKZF3) | Gopalakrishnan et al., 2016 |
| T-ALL | TG | NOTCH1 (0) | ↑ | MYC | Herranz et al., 2014 |
| T-ALL | P, A | THZ1 (S) | ↓ | RUNX1 | Kwiatkowski et al., 2014 |
| T-ALL | D, TG | TAL1/SCL (O) | ↓ | GIMAP | Liau et al., 2017 |
†Abbreviation for cancers: AL, acute leukemia; AML, acute myelocytic leukemia; B-ALL, B-cell acute lymphoblastic leukemia; BL, Burkitt lymphoma; BPDCN, blastic plasmacytoid dendritic cell neoplasm; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B cell lymphoma; ETP-ALL, early T-cell progenitor acute lymphoblastic leukemia; FL, follicular lymphoma; IL, immunosuppression-related lymphomas; LK, leukemia; LP, lymphoma; MM, multiple myeloma; PEL, primary effusion lymphoma; T-ALL, T-cell acute lymphoblastic leukemia. ‡Abbreviation for phenotypes: A, apoptosis; D, differentiation; DLT, dose-limiting toxicity; G, growth; MT, metastasis. NM: not mentioned; P: proliferation; T: transformation; TG: tumorigenesis; §Abbreviation for molecules: BETi, bromodomain inhibitor; EBV, Epstein-Barr virus; IMiDs, immunomodulatory drugs; NM, not mentioned; NPi, Notch pathway inhibitor; O, oncogenic; S, suppressor of cancer.